Veloxis Pharmaceuticals announces financial results for the first nine months of 2015

Nov 11, 2015, 17:12 ET from Veloxis Pharmaceuticals

HORSHOLM, Denmark, Nov. 11, 2015 /PRNewswire/ --

Highlights:

  • On 30 September, 2015, Veloxis had cash and cash equivalents of DKK 157.6 million, and the Company's cash position is expected to be in the range of DKK 100 – 130 million at year-end. The Company is currently engaged in a process to secure additional financing primarily through debt structure. The Company expects that the financing cost will be in the range of a high yield bond for similar life science companies and the proceeds will be used primarily to support US product launch.
  • On 14 October, 2015, a sponsored Level 1 American depositary receipt (ADR) program in the U.S. was established. The ADR trades under the symbol VXPZY.
  • Envarsus® XR has been issued a unique reimbursement J-code by the Centers for Medicare and Medicaid Services (CMS) for 2016 onwards.
  • Envarsus® XR has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus.
  • Veloxis has received U.S. Food and Drug Administration (FDA) approval of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus® XR. Veloxis expects Envarsus® XR to be available to patients in the United States and their physicians by the end of 2015.
  • Veloxis reported a net loss of DKK 114.3 million for the nine months of 2015 compared to a net profit of DKK 12.9 million for the same period in 2014. The reported net loss is in line with expectations.
  • For the first nine months of 2015, Veloxis recognized revenue of DKK 13.0 million compared to DKK 120.2 million in the same period of 2014. Revenue in 2015 consist of commercial sales to Chiesi Farmaceutici S.p.A. Revenue in 2014 consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. Envarsus is currently launched in Germany, Netherlands, UK, Denmark, Austria, Ireland, France, Slovenia and the Czech Republic.
  • For the first nine months of 2015, Veloxis' sales and marketing costs amounted to DKK 40.9 million compared to DKK 24.0 million during the same period in 2014. Research and development costs amounted to DKK 56.0 million compared to DKK 70.4 million during the same period in 2014.

Outlook for 2015
Veloxis maintains its 2015 outlook with an operating loss in the range of DKK 175 - 205 million, and a net loss in the range of DKK 155 - 185 million for the financial year 2015.

On 30 September 2015, the Company's cash position equaled DKK 157.6 million, and on 31 December 2015, the Company's cash position is expected to be in the range of DKK 100 – 130 million.

Conference call
A conference call will be held tomorrow, 12 November, 2015 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM EST (New York).

To access the live conference call, please dial one of the following numbers:
+45 38 48 75 13 (Denmark)
+44 (0) 20 7136 2055 (UK)
+1 718 354 1359 (USA)
Access code 1720884

Following the conference call, a recording will be available on the company's website http://www.veloxis.com.

Business update
Envarsus® Market and Regulatory Strategy
On 28 July, 2014, it was announced that the European Commission granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU).  Veloxis' marketing and distribution partner in EU Chiesi Farmaceutici launched Envarsus® in late 2014, with launches in Germany and the Netherlands, followed by launch in the UK, Denmark, Austria, Eire, France, Slovenia and the Czech Republic in 2015. Additional launches are anticipated for the majority of the major EU countries during 2015 and into 2016, once local requirements such as pricing and reimbursement negotiations have been completed.

On 12 June, 2015, Veloxis announced that the U.S. District Court for the District of Columbia had ruled in favor of the FDA in the lawsuit filed by Veloxis against the FDA.  The Court's ruling left intact FDA's 30 October, 2014 tentative approval of Envarsus® XR (tacrolimus extended-release tablets), which delayed full approval for use in newly transplanted kidney transplant recipients ("de novo" patients).  Veloxis submitted revised labeling to FDA with the goal of making Envarsus® XR available for kidney transplant patients who wish to convert from twice-daily tacrolimus products to once-daily Envarsus® XR.

On 10 July, 2015, Veloxis received U.S. FDA approval of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus® XR.

Envarsus® XR has been issued a unique reimbursement J-code by the Centers for Medicare and Medicaid Services (CMS) for 2016 onwards. J-codes are used by providers to identify drugs to help facilitate reimbursement.

The build and hiring of the full commercial infrastructure, including a sales team of approximately 18 individuals to call on the top 120 transplant centres in the US, to support launch of Envarsus® XR in the US is nearly complete and expected to be in place and operational for product launch in late 2015. The initial sales uptake in the US is expected to be gradual but steady as patients are converted from existing therapies to Envarsus XR.

In addition, Envarsus® XR has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus.

Envarsus® study programme
Veloxis is conducting a series of Phase IIIb/IV studies to further evaluate potential differences in clinical profile provided by Envarsus®' unique PK profile. The first study completed was the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) study of Envarsus® in kidney transplant recipients experiencing drug-induced tremors which demonstrated significant overall improvements following the switch to Envarsus®. The results of this study were published in the journal Clinical Transplantation.

Additionally, the ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of Envarsus® in kidney transplant recipients has been completed. The ASERTAA primary pharmacokinetic results were presented at the American Transplant Congress in Philadelphia in May, 2015 and at the European Society of Organ Transplantation meeting in September, 2015. The key primary outcomes from this study were:

  • The overall PK differences (increased absorption [p<0.0001], lower peak blood concentrations [p<0.0001], less peak-to-tough fluctuation in blood levels [p<0.0001]) between Envarsus XR and immediate-release tacrolimus (IR-Tac) capsules seen previously in studies of kidney transplant recipients were also confirmed in this exclusively African-American patient population.
  • The optimal conversion ratio for once-daily extended release Envarsus XR was shown to be approximately 20% lower than the total IR-Tac daily dose prior to conversion.
  • Peak tacrolimus concentration (Cmax) was reduced 30% for patients on Envarsus while intra-day fluctuation was reduced 50%.

In addition, the ASTCOFF (A STeady-state Pharmacokinetic Comparison Of all FK-506 Formulations) Phase IIIb study has been completed and primary results were announced in June, 2015 and subsequently presented at the European Society of Organ Transplantation meeting in September, 2015. This study examined the pharmacokinetic differences between Envarsus and the other two tacrolimus formulations commercially available, namely Astagraf XL and Prograf. Primary results from this study confirmed previously published data for Envarsus and showed greater bioavailability (p<0.0001) and a flatter PK profile characterized by lower peak-to-trough fluctuation (p<0.001) and delayed time to peak concentrations of 6 hrs (p=<0.001) compared to both Prograf and Astagraf. At equivalent exposure, Envarsus achieves at least a 30% dose reduction requirement and a substantively lower peak blood concentration (p=<0.005) compared to the two comparator products.

 

Financial Highlights















YTD

YTD

Q3

Q3

Year



2015

2014

2015

2014

2014



DKK'000

DKK'000

DKK'000

DKK'000

DKK'000








Income Statement






Revenue

12,955

120,181

3,379

95,769

123,395

Production costs

(7,478)

-

(1,680)

-

(3,247)

Gross profit

5,477

120,181

1,699

95,769

120,148

Sales and marketing costs

(40,863)

(24,032)

(21,406)

(10,378)

(41,278)

Research and development costs

(55,988)

(70,435)

(16,861)

(19,391)

(90,111)

Administrative expenses

(40,387)

(27,988)

(12,814)

(10,256)

(47,363)

Operating result

(131,761)

(2,274)

(49,382)

55,744

(58,604)

Net financial income / (expenses)

13,048

15,238

(280)

13,332

20,903

Result before tax

(118,713)

12,964

(49,662)

69,076

(37,701)

Tax for the period

4,436

(106)

1,479

(3,095)

1,382

Net result for the period

(114,277)

12,858

(48,183)

65,981

(36,319)








Balance Sheet






Cash and cash equivalents

157,579

310,571

157,579

310,571

270,434

Total assets

193,583

330,127

193,583

330,127

293,723

Share capital

166,374

166,300

166,374

166,300

166,300

Total equity

148,688

300,456

148,688

300,456

253,248

Investment in property, plant and equipment

322

657

50

540

1,805








Cash Flow Statement






Cash flow from operating activities

(127,079)

(35,104)

(33,381)

32,023

(77,243)

Cash flow from investing activities

(322)

(657)

(50)

(540)

(2,547)

Cash flow from financing activities

261

989

141

304

989

Cash and cash equivalents at period end

157,579

310,571

157,579

310,571

270,434








Financial Ratios






Basic and diluted EPS

(0.07)

0.01

(0.03)

0.04

(0.02)

Weighted average number of shares

1,663,194,517

1,662,020,404

1,663,408,929

1,662,680,554

1,662,266,639

Average number of employees (FTEs)

34

25

42

28

26

Assets/equity

1.30

1.10

1.30

1.10

1.16

Share price

1.22

2.07

1.22

2.07

1.15

The interim report has not been audited or reviewed by the company's independent auditors.

Revenue
For the first nine months of 2015 Veloxis recognized revenue of DKK 13.0 million compared to DKK 120.2 million in the same period of 2014. Revenue in 2015 consist of commercial sales to Chiesi Farmaceutici S.p.A. Revenue in 2014 consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. Envarsus is currently launched in Germany, Netherlands, UK, Denmark, Austria, Ireland, France, Slovenia and the Czech Republic.

Sales and marketing costs
For the first nine months of 2015, Veloxis' sales and marketing costs amounted to DKK 40.9 million compared to DKK 24.0 million during the same period in 2014. This reflects the building of the marketing and sales infrastructure in the US.

Research and development costs
For the first nine months of 2015, Veloxis' research and development costs amounted to DKK 56.0 million compared to DKK 70.4 million during the same period in 2014. The reduction in cost is associated with the overall reduction in study activity as studies are being completed.

Administrative expenses
For the first nine months of 2015, Veloxis' administrative cost amounted to DKK 40.4 million compared to DKK 28.0 million during the same period in 2014. The increase in cost is mainly attributable to legal fees in connection with legal actions against the FDA.

Compensation costs
For the first nine months of 2015, a total of DKK 9.6 million was recognized as share-based compensation. The cost is included in sales & marketing, research & development and administrative cost. The comparable cost for 2014 was DKK 7.5 million.

In the third quarter of 2015, a total of 245,339 warrants have been cancelled, a total of 392,144 warrants have been exercised (386,606 at an exercise price of DKK 0.35, 1,386 at an exercise price of DKK 0.94, 4,152 at an exercise price of DKK 0.95), a total of 107,500 warrants have expired and a total of 5,990,000 warrants at a strike price of DKK 1.06 was granted to other employees.

On 30 September, 2015, there were a total of 132,205,917 warrants outstanding at an average strike price of DKK 0.70. Members of the Board of Directors held 5,107,815 warrants at an average strike price of DKK 0.90. Members of the Executive Management held 76,170,781 warrants at an average strike price of DKK 0.59, while other current and former employees held 50,927,321 warrants at an average strike price of DKK 0.85.

Please refer to Veloxis' latest annual report for additional details on the Company's warrant programs.

Operating loss
Veloxis' operating loss for the first nine months of 2015 was DKK 131.8 million compared to DKK 2.3 million in the corresponding period of 2014.

Financial income
During the first nine months of 2015, the Company recognized net financial income of DKK 13.0 million compared to net financial income of DKK 15.2 million in the corresponding period of 2014. The income is mainly due to unrealized currency gains following an increase in the USD / DKK currency rate during the first nine months of 2015.

Net loss
Veloxis' net loss for the first nine months of 2015 was DKK 114.3 million compared to a net profit of DKK 12.9 million in the corresponding period of 2014.

Cash flow
On 30 September, 2015, the balance sheet reflects cash and cash equivalents of DKK 157.6 million compared to DKK 270.4 million on 31 December, 2014. This represents a decrease of DKK 112.8 million primarily related to the Company's operating activities for the period.

Balance sheet
On 30 September, 2015, total assets were DKK 193.6 million compared to DKK 293.7 million at the end of 2014.

Shareholders' equity equalled DKK 148.7 million on 30 September, 2015, compared to DKK 253.2 million at the end of 2014.

Significant risks and uncertainties
Veloxis faces a number of risks and uncertainties related to operations, research and development, commercial and financial activities. For further information about risks and uncertainties, we refer to the Annual Report for 2014. As of the date of this Interim Report, there have been no significant changes to Veloxis' overall risk profile since the publication of the Annual Report for 2014.



For more information, please contact:


William J. Polvino 

Johnny Stilou

President & CEO 

EVP, Chief Financial Officer

Phone: +1 732 321 3202

Phone: +45 3053 3364

Email: wjp@veloxis.com 

Email: jst@veloxis.com  



The forward looking statements and targets contained herein are based on the current view and assumptions of the Executive Management and the Board of Directors of Veloxis Pharmaceuticals A/S. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Veloxis Pharmaceuticals A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless  required by applicable law.

Envarsus® XR (tacrolimus extended-release tablets) – Important Safety Information

BOXED WARNING:  MALIGNANCIES AND SERIOUS INFECTIONS
Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death

INDICATIONS AND USAGE
ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants.
Limitation of Use: ENVARSUS XR extended-release tablets are not interchangeable or substitutable with other tacrolimus extended-release or immediate release products

CONTRAINDICATIONS
ENVARSUS XR is contraindicated in patients with known hypersensitivity to tacrolimus.

WARNINGS AND PRECAUTIONS
Immunosuppressants, including ENVARSUS XR, increase the risk of developing lymphomas and other malignancies, particularly of the skin.
Post-transplant lymphoproliferative disorder (PTLD), associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.
Immunosuppressants, including ENVARSUS XR, increase the risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes.
ENVARSUS XR is not interchangeable or substitutable with tacrolimus immediate-release products or other tacrolimus extended-release products. 
Avoid the use of live attenuated vaccines during treatment with ENVARSUS XR. Inactivated vaccines noted to be safe for administration after transplantation may not be sufficiently immunogenic during treatment with ENVARSUS XR.

Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus.

ADVERSE REACTIONS
Most common adverse reactions (incidence ≥10%) reported with ENVARUS XR are: diarrhea and blood creatinine increased.

For full Prescribing Information, see the US Package Insert and Medication Guide at www.envarsusxr.com

About Envarsus®
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after organ transplantation. Envarsus® (tacrolimus prolonged-release tablets) has received marketing authorization in the EU for prophylaxis of organ rejection in kidney and liver transplant recipients. In the U.S., Envarsus®, known as Envarsus® XR (tacrolimus extended-release tablets), is approved for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations. Envarsus® XR has received orphan drug designation in the U.S. Veloxis plans to commercialize Envarsus® XR in the U.S. through its own sales force and in the EU through its partnership with Chiesi Farmaceutici SpA. 

About Veloxis Pharmaceuticals
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

Executive Management's and the Board of Directors' Statement on the Interim Report

The Executive Management and the Board of Directors have considered and adopted the Interim Report for the 9 months ended 30 September 2015 of Veloxis Pharmaceuticals A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces.

Horsholm, 11 November, 2015


Executive Management




Dr. William J. Polvino 

Johnny Stilou

President & CEO

Executive Vice President & CFO 





Board of Directors




Mette Kirstine Agger 

Thomas Dyrberg

(Chairman)

(Deputy Chairman)



Anders Gotzsche 

Michael Heffernan 

 

 

Financial Highlights









Quarterly Numbers in DKK





















Q3

Q2

Q1


Q4

Q3

Q2

Q1



2015

2015

2015


2014

2014

2014

2014



DKK'000

DKK'000

DKK'000


DKK'000

DKK'000

DKK'000

DKK'000











Income Statement









Revenue

3,379

5,292

4,284


3,214

95,769

12,206

12,206

Production costs

(1,680)

(1,657)

(4,141)


(3,247)

-

-

-

Gross profit

1,699

3,635

143


(33)

95,769

12,206

12,206

Sales and marketing costs

(21,406)

(9,637)

(9,820)


(17,246)

(10,378)

(13,653)

-

Research and development costs

(16,861)

(18,363)

(20,764)


(19,677)

(19,391)

(24,420)

(26,624)

Administrative expenses

(12,814)

(11,549)

(16,024)


(19,375)

(10,256)

(9,983)

(7,749)

Operating result

(49,382)

(35,914)

(46,465)


(56,331)

55,744

(35,850)

(22,167)

Net financial income / (expenses)

(280)

(4,673)

18,000


5,666

13,332

1,228

677

Result before tax

(49,662)

(40,587)

(28,465)


(50,665)

69,076

(34,622)

(21,490)

Tax for the period

1,479

1,478

1,480


1,488

(3,095)

1,495

1,494

Net result for the period

(48,183)

(39,109)

(26,985)


(49,177)

65,981

(33,127)

(19,996)











Balance Sheet









Cash and cash equivalents

157,579

191,064

233,568


270,434

310,571

264,240

296,237

Total assets

193,583

224,177

262,656


293,723

330,127

276,493

305,373

Share capital

166,374

166,334

166,309


166,300

166,300

166,252

166,252

Total equity

148,688

193,526

228,715


253,248

300,456

231,649

261,538

Investment in property, plant and equipment

50

272

-


1,149

540

(169)

285











Cash Flow Statement









Cash flow from operating activities

(33,381)

(37,205)

(56,494)


(42,139)

32,023

(33,577)

(33,550)

Cash flow from investing activities

(50)

(272)

-


(1,891)

(540)

169

(285)

Cash flow from financing activities

141

88

33


-

304

-

684

Cash and cash equivalents at period end

157,579

191,064

233,568


270,434

310,571

264,240

296,237











Financial Ratios









Basic and diluted EPS

(0.03)

(0.02)

(0.02)


(0.03)

0.04

(0.02)

(0.01)

Weighted average number of shares

1,663,408,929

1,663,167,653

1,663,002,504


1,662,997,314

1,662,680,554

1,662,527,283

1,660,833,074

Average number of employees (FTEs)

42

31

30


31

28

23

22

Assets/equity

1.30

1.16

1.15


1.16

1.10

1.19

1.17

 

 


Income statement and statement of comprehensive income



Income Statement

Consolidated








(DKK'000)

YTD

YTD

Q3

Q3

Year



2015

2014

2015

2014

2014








Revenue

12,955

120,181

3,379

95,769

123,395

Production costs

(7,478)

-

(1,680)

-

(3,247)








Gross profit

5,477

120,181

1,699

95,769

120,148








Sales and marketing costs

(40,863)

(24,032)

(21,406)

(10,378)

(41,278)

Research and development costs

(55,988)

(70,435)

(16,861)

(19,391)

(90,111)

Administrative expenses

(40,387)

(27,988)

(12,814)

(10,256)

(47,363)








Operating result

(131,761)

(2,274)

(49,382)

55,744

(58,604)








Financial income

13,232

15,432

-

13,526

21,098

Financial expenses

(184)

(194)

(280)

(194)

(195)








Result before tax

(118,713)

12,964

(49,662)

69,076

(37,701)








Tax for the period

4,436

(106)

1,479

(3,095)

1,382








Net result for the period

(114,277)

12,858

(48,183)

65,981

(36,319)








Basic and diluted EPS

(0.07)

0.01

(0.03)

0.04

(0.02)








Weighted average number of shares

1,663,194,517

1,662,020,404

1,663,408,929

1,662,680,554

1,662,266,639















Statements of comprehensive income

Consolidated








(DKK'000)

YTD

YTD

Q3

Q3

Year



2015

2014

2015

2014

2014








Net result for the period

(114,277)

12,858

(48,183)

65,981

(36,319)

  Other comprehensive income:






  Items that may be subsequently reclassified






  to profit or loss:






  Currency translation differences, net of tax

(144)

22

104

(52)

(208)








  Other comprehensive income for the period

(144)

22

104

(52)

(208)








Total comprehensive income for the period

(114,421)

12,880

(48,079)

65,929

(36,527)

 

 


Balance sheet














Assets




Consolidated











(DKK'000)


30 Sep.


30 Sep.


31 Dec.




2015


2014


2014









Patent rights and software


1,034


415


1,134









Intangible assets


1,034


415


1,134









Property, plant and equipment


3,654


3,411


4,247









Property, plant and equipment


3,654


3,411


4,247









Non-current assets


4,688


3,826


5,381









Inventories


10,163


7,567


4,764









Trade receivables


-


-


25

Tax receivables


10,937


-


6,250

Other receivables


4,845


7,568


2,677

Prepayments


5,371


595


4,192









Receivables


21,153


8,163


13,144









Cash


157,579


310,571


270,434









Cash and cash equivalents


157,579


310,571


270,434









Current assets


188,895


326,301


288,342









Assets


193,583


330,127


293,723

 

 


Balance sheet














Equity & Liabilities




Consolidated











(DKK'000)


30 Sep.


30 Sep.


31 Dec.




2015


2014


2014









Share capital


166,374


166,300


166,300

Special reserve


407,289


407,289


407,289

Translation reserves


1,616


1,990


1,760

Retained earnings/loss


(426,591)


(275,123)


(322,101)









Equity


148,688


300,456


253,248









Trade payables


15,598


10,650


17,875

Tax payables


761


-


470

Other payables


28,536


19,021


22,130









Current liabilities


44,895


29,671


40,475









Liabilities


44,895


29,671


40,475









Equity and liabilities


193,583


330,127


293,723

 

 


Cash flow statements




Cash Flow Statement

Consolidated








(DKK'000)

YTD

YTD

Q3

Q3

Year



2015

2014

2015

2014

2014








Operating result

(131,761)

(2,274)

(49,382)

55,744

(58,604)








Share-based payment

9,600

7,545

3,100

2,575

9,744

Depreciation and amortization

1,094

658

380

253

993

Changes in working capital

(5,828)

(36,873)

12,595

(22,175)

(26,194)








Cash flow from operating activities before interest

(126,895)

(30,944)

(33,307)

36,397

(74,061)








Interest received

-

212

-

(2)

350

Interest paid

(184)

(194)

(74)

(194)

(195)

Corporate tax received

-

-

-

-

1,250

Corporate tax paid

-

(4,178)

-

(4,178)

(4,587)








Cash flow from operating activities

(127,079)

(35,104)

(33,381)

32,023

(77,243)















Purchase of property, plant and equipment

(322)

(657)

(50)

(540)

(2,547)








Cash flow from investing activities

(322)

(657)

(50)

(540)

(2,547)















Proceeds from issuance of shares, net

261

989

141

304

989








Cash flow from financing activities

261

989

141

304

989















Increase/(decrease) in cash

(127,140)

(34,772)

(33,290)

31,787

(78,801)

Cash at beginning of period

270,434

328,652

191,064

264,240

328,652

Exchange gains/(losses) on cash

14,285

16,691

(195)

14,544

20,583








Cash at end of period

157,579

310,571

157,579

310,571

270,434

 

 

Statement of changes in equity













Consolidated Equity










Number of Shares


Share Capital

Special Reserves

Translation Reserves

Retained Earnings

Total





DKK'000

DKK'000

DKK'000

DKK'000

DKK'000










Equity as of 1 Jan. 2014

1,660,572,426


166,057

407,289

1,968

(296,272)

279,042










Net result for the period






12,858

12,858

Other comprehensive income for the period




22


22

Total comprehensive income





22

12,858

12,880










Warrant exercises

2,424,888


243



746

989

Share-based payment






7,545

7,545










Equity as of 30 Sep. 2014

1,662,997,314


166,300

407,289

1,990

(275,123)

300,456










Net result for the period






(49,177)

(49,177)

Other comprehensive income for the period




(230)


(230)

Total comprehensive income





(230)

(49,177)

(49,407)










Share-based payment






2,199

2,199










Equity as of 31 Dec. 2014

1,662,997,314


166,300

407,289

1,760

(322,101)

253,248










Net result for the period






(114,277)

(114,277)

Other comprehensive income for the period




(144)


(144)

Total comprehensive income





(144)

(114,277)

(114,421)










Warrant exercises

735,560


74



187

261

Share-based payment






9,600

9,600










Equity as of 30 Sep. 2015

1,663,732,874


166,374

407,289

1,616

(426,591)

148,688

 

Notes

1.         Accounting policies
The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of Veloxis Pharmaceuticals' annual report for 2014.

2.         Research and development costs
We track research and development costs by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development costs include personnel, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities, medical affairs and other costs including cost of premises, depreciation and amortization related to research and development activities. Research and development costs are charged to operations as incurred.

 

 

SOURCE Veloxis Pharmaceuticals



RELATED LINKS

http://www.veloxis.com